진행된 자궁경부암에서 방사선치료 단독과 항암 화학요법 및 방사선치료 병용요법의 결과

Abstract

목적 : 진행된 자궁경부암에서 방사선치료 단독과 비교하여 항암화학요법과 방사선 병용치료의 성적을 후향적으로 분석하였다. 재료 및 방법 : 계명대학교 동산의료원 치료방사선과에서 1988년 6월부터 1993년 12월까지 FIGO병기 IIb, III, IV자궁경부암으로 근치적 방사선치료를 받은 76명의 환자를 대상으로 하였다. 모든 환자는 외부방사선치료와 강내방사선치료를 시행받았다. 방사선 단독으로 치료한 환자는 36명이었고 Cisplatin을 포함한 항암화학요법후 방사선치료를 시행한 환자는 40명이었다. 병기는 FIGO 분류상 IIb가 48명. IIIa가 3명, IIIb가 23명, IVa가 2명이었고 환자의 평균 연령은 53세이었고 환자의 추적기간은 7개월에서 95개월로 중앙추적기간은 58개월이었다. 결과 :완전관해는 방사선치료 단독군은 31명 (86.1%), 병용치료군은 32명 (80%)로 통계적으로 유의한 차이가 없었다. 전체 환자의 5년생존률은 67.3%이었고 병기별 5년 생존률은 IIb가 74%, IIIa는 66.7%, IIIb는 49.8%, IVa는 50%이었다. 치료방법에 따른 5년생존률은 방사선치료단독군은 74.1%, 병용치료군은 61.4%(P=0.4)로 통계적으로 유의한 차이가 없었다. 5년 무병생존률은 방사선치료 단독군은 65.8%, 병용치료군은 57.5%(P=0.27)이었고 5년 국소제어률은 방사선치료 단독군은 71.5%, 병용치료군은 60%(P=0.17)이었으며 5년 원격제어률은 방사선치료 단독군은 80.7%, 병용치료군은 89.9%(P=0.42)이었다. 치료에 따른 골수억제는 방사선치료 단독군에서 4명 (11.1%), 병용치료군에서는 9명 (22.5%)가 관찰되었다. Grade 11 방광염이 방사선치료 단독군에서 2명에서 관찰 되었고 grade II 직장염이 방사선치료 단독군에서 2명, 병행치료군에서 2명, 외과적 수술이 필요했던 직장천공 1명과 보존적으로 치료된 장폐쇄 1명이 방사선치료 단독군에서 관찰되었다. 치료에 따른 부작용은 양군간에 유의한 차이가 없었다. 결 론:진행된 자궁경부암에서 방사선치료 단독군과 비교하여 항암화학요법과 방사선 병용요법이 생존률, 치료실패, 부작용 등에 영향을 미치지 않았다.

Purpose : This is retrospective study to compare the results of radiation therapy alone and neoadjuvant chemotherapy and radiation in advanced stage of uterine cervical cancer. Materials and Methods : Seventy-six Patients who were treated with definitive radiation therapy for locally advanced cervical cacinoma between June 1988 and December 1993 at the department of radiation oncology, Keimyung University Dong-san Hospital. Thirty six patients were treated with radiation therapy alone and forty patients were treated with cisplatin based neoadjuvant chemotherapy and radiation therapy. According to FIGO staging system. there were 48 patients in stage IIb, 3 patients in stage IIIa, 23 patients in stage lIIb and two patients in stage IVa with median age of 53 years old. Follow-up periods ranged from 7 to 95 months with median 58 months. Results : Complete response (CR) rate were 86.1% in radiation alone group and 80% in chemoradiation group. There was no statistical difference in CR rate between the two groups. Overall five-year survival rate was 67.3%. According to stage, overall five-rear survival rates were 74% in stage IIb, 66.7% in stage IIIa, 49.8% in stage IIb, 50% in stage IVa. According to treatment modality overall five year survival rates were 74.1% in radiation alone and 61.4% in chemoradiation group (P=0.4) Five rear local failure free survival rates were 71.5% in radiation alone group and 60% in chemoradiation group (P=0.17). Five year distant metastasis free survival rates were 80.7% in radiation aione group and 89.9% in chemoradiation group (P=0.42). Bone marrow suppression (more than noted in 3 cases of radiaion alone group and 1 case of chemoradiation group. Grade II retal complication was noted in 5 patients of radiation group and 4 patients In chemoradiation group. Bowel obstruction treated with conservative treatment (1 patient) and bowel perforation treated with surgery (1 patient) were noted in radiation alone group. There was no statistical difference in complication between two groups. Conclusion : There was no statistical difference in survival, failure and complication between neoadjuvant chemotherapy and radiation versus radiation alone in locally advanced uterine cervical carcinoma.